Skip Navigation


JAC Advance Access originally published online on July 7, 2005
Journal of Antimicrobial Chemotherapy 2005 56(2):365-371; doi:10.1093/jac/dki241
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/2/365    most recent
dki241v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Girard, D.
Right arrow Articles by Lame, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Girard, D.
Right arrow Articles by Lame, M. E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models

D. Girard*, S. M. Finegan, M. W. Dunne and M. E. Lame

Pfizer Global Research and Development, Groton Laboratories, Groton, CT 06340, USA

Received 17 February 2005; returned 4 May 2005; revised 3 June 2005; accepted 10 June 2005


* Corresponding author. Fax: +1-860-686-5301; E-mail: dennis.girard{at}pfizer.com

Objectives: As a result of the prolonged half-life and unique pharmacokinetic and pharmacodynamic (PK-PD) characteristics of azithromycin, shorter dosing regimens are being evaluated for the treatment of community-acquired infections. To provide further support for a shorter dosing regimen, the efficacy of azithromycin was determined in preclinical infection models comparing single- versus multi-dose regimens.

Methods: The efficacy of single versus multi-dose regimens of azithromycin was compared in mouse pneumonia, acute peritonitis, and neutropenic thigh infection models and in a gerbil model of Haemophilus influenzae acute otitis media. Azithromycin was administered as a single oral dose on the first treatment day, or as two divided doses over 2 treatment days, or as three divided doses over 3 treatment days. The pharmacokinetics of azithromycin was profiled following single and multi-dose regimens with the single dose data fit to an Emax model to characterize the PK-PD of azithromycin.

Results: In the mouse efficacy models, administration of single-dose azithromycin produced superior rates of survival and bacterial clearance compared with the same total dose divided over 2 or 3 days. In the gerbil model, a single dose sterilized the middle ear and more rapidly cleared H. influenzae. The pharmacokinetic evaluation confirmed similar total exposure (AUC) in serum and pulmonary tissue for the three regimens. Correlation of PK-PD parameters and antimicrobial efficacy confirmed a concentration-dependent and dosing-independent relationship for azithromycin.

Conclusions: These data are consistent with data reported from clinical studies and indicate that a single-dose regimen would be at least as effective as the same dose administered over several days.

Keywords: azithromycin , clarithromycin , amoxicillin/clavulanate , single-dose regimen , acute otitis media , Haemophilus influenzae , Streptococcus pneumoniae


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
M. Lucchi, B. Damle, A. Fang, P. J. de Caprariis, A. Mussi, S. P. Sanchez, G. Pasqualetti, and M. Del Tacca
Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin
J. Antimicrob. Chemother., April 1, 2008; 61(4): 884 - 891.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
K. Yanagihara, Y. Morinaga, S. Nakamura, M. Seki, K. Izumikawa, H. Kakeya, Y. Yamamoto, Y. Yamada, S. Kamihira, and S. Kohno
Subinhibitory concentrations of telithromycin, clarithromycin and azithromycin reduce methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo
J. Antimicrob. Chemother., March 1, 2008; 61(3): 647 - 650.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
P. Liu, H. Allaudeen, R. Chandra, K. Phillips, A. Jungnik, J. D. Breen, and A. Sharma
Comparative Pharmacokinetics of Azithromycin in Serum and White Blood Cells of Healthy Subjects Receiving a Single-Dose Extended-Release Regimen versus a 3-Day Immediate-Release Regimen
Antimicrob. Agents Chemother., January 1, 2007; 51(1): 103 - 109.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.